Literature DB >> 17220285

EGFR mutations in exons 18-21 in sporadic breast cancer.

D Generali1, R Leek2, S B Fox3, J W Moore1, C Taylor4, P Chambers4, A L Harris5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17220285     DOI： 10.1093/annonc/mdl322

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  12 in total

1.  Very low prevalence of epidermal growth factor receptor (EGFR) protein expression and gene amplification in Saudi breast cancer patients.

Authors:  Mohamed A Shawarby; Dalal M Al-Tamimi; Ayesha Ahmed
Journal:  Diagn Pathol       Date:  2011-06-24       Impact factor: 2.644

2.  Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.

Authors:  Yvonne Hui-Fang Teng; Wai-Jin Tan; Aye-Aye Thike; Poh-Yian Cheok; Gary Man-Kit Tse; Nan-Soon Wong; George Wai-Cheong Yip; Boon-Huat Bay; Puay-Hoon Tan
Journal:  Breast Cancer Res       Date:  2011-04-01       Impact factor: 6.466

3.  FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice.

Authors:  Sun-Young Lee; Roland Meier; Saori Furuta; Marc E Lenburg; Paraic A Kenny; Ren Xu; Mina J Bissell
Journal:  J Clin Invest       Date:  2012-08-13       Impact factor: 14.808

Review 4.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

5.  Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.

Authors:  Kelly L Mueller; Julie M Madden; Gina L Zoratti; Charlotte Kuperwasser; Karin List; Julie L Boerner
Journal:  Breast Cancer Res       Date:  2012-07-12       Impact factor: 6.466

6.  Worldwide variations in EGFR somatic mutations: a challenge for personalized medicine.

Authors:  Pierre-Jean Lamy; William Jacot
Journal:  Diagn Pathol       Date:  2012-02-01       Impact factor: 2.644

7.  Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles.

Authors:  William Jacot; Evelyne Lopez-Crapez; Simon Thezenas; Romain Senal; Frédéric Fina; Frédéric Bibeau; Gilles Romieu; Pierre-Jean Lamy
Journal:  Breast Cancer Res       Date:  2011-12-22       Impact factor: 6.466

8.  The epidermal growth factor receptor (EGFR / HER-1) gatekeeper mutation T790M is present in European patients with early breast cancer.

Authors:  Vahid Bemanian; Torill Sauer; Joel Touma; Bjørn Arne Lindstedt; Ying Chen; Hilde Presterud Ødegård; Katja Marjaana Vetvik; Ida Rashida Bukholm; Jürgen Geisler
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

9.  Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations.

Authors:  V Secq; J Villeret; F Fina; M Carmassi; X Carcopino; S Garcia; I Metellus; L Boubli; J Iovanna; C Charpin
Journal:  Br J Cancer       Date:  2014-01-14       Impact factor: 7.640

Review 10.  FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance.

Authors:  Courtney A Bartel; Neetha Parameswaran; Rocky Cipriano; Mark W Jackson
Journal:  Oncotarget       Date:  2016-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.